| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/20/2007 | US7192616 Slow down or even inhibit cellular differentiation and/or proliferation. |
| 03/20/2007 | US7192582 Human monoclonal antibodies to FC alpha receptor (CD89) |
| 03/20/2007 | CA2433518C Method for producing the anticholinergic tiotropium bromide |
| 03/20/2007 | CA2411787C Stable gabapentin having ph within a controlled range |
| 03/20/2007 | CA2360655C Pharmaceutical compositions |
| 03/20/2007 | CA2162154C Use of a transition metal complex for the treatment of septic shock |
| 03/16/2007 | WO2006028277A1 A pharmaceutical composition for treating ataxia, multiple system atrophy or balance disorders |
| 03/15/2007 | WO2007030618A2 Bicyclic derivatives as modulators of voltage gated ion channels |
| 03/15/2007 | WO2007030537A1 Topical formulations containing o-desmethyl venlafaxine (odv) or its salts |
| 03/15/2007 | WO2007030150A1 Dihydrobenzofuranyl alkanamine derivatives as 5ht2c agonists |
| 03/15/2007 | WO2007030080A1 Heterocyclic compounds |
| 03/15/2007 | WO2007030035A1 Agent for correcting stress-inducing neuro-mediator, neuro- endocrine and metabolic disturbances and method for preventing and treating concomitant pathological conditions |
| 03/15/2007 | WO2007029847A1 Bicyclic aromatic substituted pyridone derivative |
| 03/15/2007 | WO2007029587A1 β SECRETASE INHIBITOR |
| 03/15/2007 | WO2007029077A1 Substituted indazoles as inhibitors of phosphodiesterase type-iv |
| 03/15/2007 | WO2007028905A1 Use of agomelatine in order to obtain medicaments which are intended for the treatment of sleep disorders among depressed patients |
| 03/15/2007 | WO2007028904A1 Novel combination between agomelatine and a noradrenaline reuptake inhibitor and pharmaceutical compositions containing same |
| 03/15/2007 | WO2007028903A1 Novel combination between agomelatine and a thymoregulating agent and pharmaceutical compositions containing same |
| 03/15/2007 | WO2007028849A1 Pyrazolecarboxamide derivatives, method of obtaining same and use thereof as inverse antagonists/agonists of the cannabinoid cb1 and opioid mu receptor |
| 03/15/2007 | WO2007028821A2 Treatment of autoimmune diseases |
| 03/15/2007 | WO2007028812A2 Selected cgrp antagonists method for production and use thereof as medicament |
| 03/15/2007 | WO2007028769A1 Monoamine neurotransmitter re-uptake inhibitor for neuroprotection |
| 03/15/2007 | WO2007028654A1 Pyridine derivatives and their use in the treatment of psychotic disorders |
| 03/15/2007 | WO2007028638A1 Fused and spirocycle compounds and the use thereof |
| 03/15/2007 | WO2007002220A3 Aminoacetamide acyl guanidines as beta-secretase inhibitors |
| 03/15/2007 | WO2006138714A3 Naphthyridine compounds |
| 03/15/2007 | WO2006138528A3 Tricyclic opioid modulators |
| 03/15/2007 | WO2006133164A3 Anti-trkb monoclonal antibodies and uses thereof |
| 03/15/2007 | WO2006121919A8 Methods of treating obsessive compulsive disorder |
| 03/15/2007 | WO2006121560A3 Methods and compositions for treatment of cns disorders |
| 03/15/2007 | WO2006083795A8 Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia |
| 03/15/2007 | WO2006047288A3 Asymmetric synthesis of dihydrobenzofuran derivatives |
| 03/15/2007 | WO2005063745A8 Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof |
| 03/15/2007 | WO2003068169A3 Stabilized synthetic immunogen delivery system |
| 03/15/2007 | US20070060752 1-Phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases |
| 03/15/2007 | US20070060647 Gene expression regulating agent |
| 03/15/2007 | US20070060594 Pyridinyl acetonitriles |
| 03/15/2007 | US20070060591 Amine substituted (dihydro- or tetrahydro-)quinoline, pyranopyridine, thiapyranopyridine, or naphthyridine derivatives as chemokine receptor modulators; lymphadenopathy associated, human T-cell leukemia/lymphoma, and/or feline immunodeficiency virus infections |
| 03/15/2007 | US20070060587 Indane derivates as muscarinic receptor agonists |
| 03/15/2007 | US20070060583 2-tert-Butyl-N,N-diethyl-1-{[1-methylpiperidin-2-yl]methyl}-1H-benzimidazole-5-carboxamide; cannabinoid receptors agonists; analgesic, anticarcinogenic, antiinflammatory, anxiolytic agent; neurodegenerative diseases; gastrointestinal and cardiovascular disorders |
| 03/15/2007 | US20070060581 1-Sulfonylindole derivatives, their preparation and their use as 5-ht6 ligands |
| 03/15/2007 | US20070060574 Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
| 03/15/2007 | US20070060572 e.g., 2-(5-fluoro-2-tolyl)-4-(4-aminocarbonylpiperazinylmethyl)-6-[a-aminocarbonyl-2,6-dichlorobenzyl]pyridine; mitogen-activated protein kinase inhibitor; antiinflammatory agent, autoimmune diseases |
| 03/15/2007 | US20070060571 e.g. 4-(5-(4-Chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl)benzenesulfonamide and nitric oxide donor (S-nitrosothiols, nitrites, nitrates, N-oxo-N-nitrosamines, sabstrate of nitric oxide synthase); analgesics, antiinflammatory agent, wound healing; gastrointestinal disorders; side effect reduction |
| 03/15/2007 | US20070060569 Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors |
| 03/15/2007 | US20070060568 5HT2c receptor modulators |
| 03/15/2007 | US20070060546 Novel use of mifepristone and derivatives therefor as hedgehog protein signaling pathway modulators and applications of same |
| 03/15/2007 | US20070060538 Gene expression inhibition; sustained release; for reduction of neuronal cell death, inflammation, and scar formation; improves wound healing, skin rejuvenation and thickening |
| 03/15/2007 | US20070060502 Substituted propane phosphinic acid derivatives |
| 03/15/2007 | US20070059831 Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis |
| 03/15/2007 | US20070059369 Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders |
| 03/15/2007 | US20070059290 Transcriptional regulation of target genes |
| 03/15/2007 | DE102004002885B4 Neue medizinisch einsetzbare Pyrrolalkaloide: Verfahren zu ihrer Isolierung, Synthese, sie enthaltende Arzneimittel und deren Verwendung New medical usable pyrrole alkaloids: methods for their isolation, synthesis, pharmaceutical compositions containing them and their use |
| 03/15/2007 | CA2643205A1 Agent for correcting stress-inducing neuro-mediator, neuro- endocrine and metabolic disturbances and method for preventing and treating concomitant pathological conditions |
| 03/15/2007 | CA2622076A1 Bicyclic derivatives as modulators of voltage gated ion channels |
| 03/15/2007 | CA2621564A1 Pyridine derivatives and their use in the treatment of psychotic disorders |
| 03/15/2007 | CA2621560A1 Modulation of neurogenesis by hdac inhibition |
| 03/15/2007 | CA2621470A1 Bicyclic aromatic substituted pyridone derivative |
| 03/15/2007 | CA2621445A1 Amino acid derivatives as histone deacetylase (hdac) inhibitors |
| 03/15/2007 | CA2621443A1 Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors |
| 03/15/2007 | CA2620554A1 Treatment of autoimmune diseases |
| 03/15/2007 | CA2620164A1 Topical formulations containing o-desmethyl venlafaxine (odv) or its salts |
| 03/15/2007 | CA2605932A1 Dihydrobenzofuranyl alkanamine derivatives as 5ht2c agonists |
| 03/14/2007 | EP1762569A1 Novel 6-amino-morphinan derivatives, method of manufacturing them and their application as analgesics |
| 03/14/2007 | EP1762568A1 Pyrazole derivatives |
| 03/14/2007 | EP1762244A1 Bmp-9 compositions for inducing differentiation of cholinergic neurons |
| 03/14/2007 | EP1762243A1 Factor for regulation of neurite growth |
| 03/14/2007 | EP1762239A1 Lofexidine for intraspinal administration |
| 03/14/2007 | EP1762238A1 New association of agomelatine with a mood stabilizer, and pharmaceutical compositions comprising them |
| 03/14/2007 | EP1762237A1 Use of agomelatine for the preparation of medicaments for the treatment of sleep disorders in depressed patients |
| 03/14/2007 | EP1761541A1 Pyrrazolo-pyrimidine derivatives |
| 03/14/2007 | EP1761533A1 1-aza-bicyclo[3.3.1]nonanes |
| 03/14/2007 | EP1761530A1 New derivatives of 5-aryl-1h-pyrrolo [2, 3b] pyridine-3-carboxamide or 5-aryl-1h-pyrrolo [2, 3b] pyridine-3-carboxylic acid |
| 03/14/2007 | EP1761524A1 Phenyl diazepane carboxamides and annelated phenyl piperazine carboxamides containing oxygen and used as dopamine d3 antagonists |
| 03/14/2007 | EP1761518A1 Novel alkyl substituted piperidine derivatives as monoamine neurotransmitter re-uptake inhibitors |
| 03/14/2007 | EP1761514A1 Novel tetracyclic tetrahydrofuran derivatives |
| 03/14/2007 | EP1761513A1 Tetracyclic compounds as estrogen ligands |
| 03/14/2007 | EP1761512A1 Novel alkyl substituted piperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 03/14/2007 | EP1761508A1 Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects |
| 03/14/2007 | EP1761507A1 Phosphodiesterase-inhibiting compounds of the 2,3-benzodiazepine type |
| 03/14/2007 | EP1761496A2 Non-imidazole heterocyclic compounds as histamine h3-receptor ligands |
| 03/14/2007 | EP1761493A2 Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 03/14/2007 | EP1761492A1 1-benzyl-4-¬(5,6-dimethoxy-1-indanone)-2-yl| methyl piperidine oxalate (donepezil oxalate) and its polymorphs |
| 03/14/2007 | EP1761488A1 Lactam tachykinin receptor antagonists |
| 03/14/2007 | EP1761485A1 Amidino compounds as cysteine protease inhibitors |
| 03/14/2007 | EP1761480A2 New mao-b inhibitors |
| 03/14/2007 | EP1761267A1 Diazabicyclic histamine-3 receptor antagonists |
| 03/14/2007 | EP1761261A1 Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| 03/14/2007 | EP1694318B1 (s)-2-n-propylamino-5-hydroxytetralin as a d3-agonist |
| 03/14/2007 | EP1511728B1 Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics |
| 03/14/2007 | EP1448235B1 Oral controlled release pharmaceutical compositions of 5,8,14-triazatetracyclo 10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene |
| 03/14/2007 | EP1406897B1 Compounds |
| 03/14/2007 | EP1259262B1 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 03/14/2007 | EP1242083B1 Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them |
| 03/14/2007 | EP1216031B1 Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing |
| 03/14/2007 | EP1171101B1 Method for producing a water-insoluble amorphous controlled release matrix |
| 03/14/2007 | EP1163226B1 Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity |
| 03/14/2007 | EP1011637B1 Modulation of drug loading in multivesicular liposomes |
| 03/14/2007 | EP0998471B1 Substituted heterocyclic compounds, method for preparing and compositions containing same |
| 03/14/2007 | EP0975351B1 Treatment of multiple sclerosis through ingestion of copolymer-1 |